Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate

BMC Psychiatry

Larry Alphs²  Ibrahim Turkoz¹  Cynthia A Bossie²  Dong-Jing Fu²  Jennifer Kern Sliwa² 

[1] Janssen Research & Development, LLC, NJ, USA;Janssen Scientific Affairs, LLC, NJ, USA

关键词: Weight;    Schizophrenia;    Paliperidone;    Metabolic;    Body mass index;   

Others  :  1123755
DOI  :  10.1186/1471-244X-14-52

 received in 2013-03-21, accepted in 2014-02-17,  发布年份 2014

【 摘 要 】

Background

There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate (PP) in a long-term trial.

Methods

We conducted a post hoc analysis of data from a PP study that included a 33-week open-label transition (TR) and maintenance phase; a variable duration, randomized, double-blind (DB), placebo-controlled phase and a 52-week open-label extension (OLE) phase. Overall, 644 patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI (kg/m²): underweight (BMI <19; n = 29, 4.5%), normal-weight (BMI 19- < 25; n = 229, 35.6%), overweight (BMI 25- < 30; n = 232, 36.0%) and obese (BMI ≥30; n = 154, 23.9%). Metabolic treatment-emergent adverse events (TEAEs) and changes in related laboratory results from TR baseline were analyzed.

Results

PP exposure was similar across BMI groups; overall mean (SD) dose/month was 70.3 (17.17) mg eq. [109.6 (26.78) mg]; median duration of exposure was 204 days (6 to 1009 days). Occurrences of metabolic TEAEs overall by group were 0% (underweight), 14.9% (normal-weight), 14.7% (overweight), and 24.0% (obese). The most common (≥2%) metabolic TEAE were weight gain and elevated blood levels of glucose, lipids, and insulin. Mean BMI and weight increased in normal-weight and overweight groups at DB endpoint, and in underweight, normal-weight and overweight groups at OLE endpoint (p ≤0.05). No consistent trend for increased metabolic-related laboratory values by baseline BMI group was observed. Homeostatic model assessments for insulin resistance indicated preexisting insulin resistance at baseline, with minimal changes at OLE endpoint across baseline BMI groups.

Conclusion

Occurrences of metabolic-related TEAEs trended with greater BMI status in patients with schizophrenia treated with PP; consistent trends in metabolic-related laboratory values were not observed.

Trial registration

This study is registered at ClinicalTrials.gov (NCT 00518323).

【 授权许可】

   
2014 Sliwa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Schultz SH, North SW, Shields CG: Schizophrenia: a review. Am Fam Physician 2007, 75(12):1821-1829.
• [2]Balf G, Stewart TD, Whitehead R, Baker RA: Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 2008, 10(1):15-24.
• [3]McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001, 46(3):273-281.
• [4]Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000, 41(4):369-370.
• [5]Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O: Glucose intolerance with atypical antipsychotics. Drug Saf 2002, 25(15):1107-1116.
• [6]Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160(2):290-296.
• [7]McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32.
• [8]Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M: The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011, 26(6):291-302.
• [9]Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF: Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007, 61(8):1356-1370.
• [10]Lean ME, Pajonk FG: Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003, 26(5):1597-1605.
• [11]Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161(8):1334-1349.
• [12]American Diabetes Association: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27(2):596-601.
• [13]INVEGA® SUSTENNA® Prescribing Information: INVEGA® SUSTENNA® paliperidone palmitate prescribing information September 2011. 2011. (Accessed on 27 April 2012) Available at: http://www.invegasustenna.com/important-product-information webcite
• [14]Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M: Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116(2–3):107-117.
• [15]Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010, 25(5):685-697.
• [16]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
• [17]Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495.
• [18]Kagal UA, Torgal SS, Patil NM, Malleshappa A: Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study. J Pharm Pract 2012, 25(3):368-373. Epub 2012
• [19]Pramyothin P, Khaodhiar L: Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010, 17(5):460-466.
• [20]Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L’Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006, 163(10):1821-1825.
• [21]McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164(7):1050-1060.
• [22]Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose–response study. Int Clin Psychopharmacol 2010, 25(5):247-256.
• [23]Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13(5):635-647.
• [24]Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010, 35(10):2072-2082.
• [25]Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010, 30(3):235-244.
• [26]Ucok A, Gaebel W: Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008, 7(1):58-62.
• [27]Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62(Suppl 7):22-31.
• [28]Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008, 30(12):2378-2386.
• [29]Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L: Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry 2013, 12(1):22. BioMed Central Full Text
• [30]Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 2012, 12:26. doi:10.1186/1471-1244X-1112-1126 BioMed Central Full Text